Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Tremblay

Showing results (11-20 of 109) with videos related to

Pageof 11
Sort By:
Cells|April 30, 2021
Next Generation Therapeutics for the Treatment of MyelofibrosisDouglas Tremblay, John Mascarenhas
Best Practice & Research. Clinical Haematology|November 4, 2022
Addressing symptom burden in myeloproliferative neoplasmsDouglas Tremblay, Ruben Mesa
Leukemia & Lymphoma|October 25, 2024
Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategiesSerena Tharakan, Douglas Tremblay, Jacques Azzi
Acta Haematologica|April 7, 2021
The Efficacy of Etoposide-Based Therapy in Adult Secondary Hemophagocytic LymphohistiocytosisLeonard Naymagon, Douglas Tremblay, John Mascarenhas
Current Hematologic Malignancy Reports|July 4, 2025
Contemporary CMML Risk Stratification and ManagementDahniel Sastow, Arjun Syal, Douglas Tremblay
Blood Reviews|July 31, 2023
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatmentChristina Darwish, Kyle Farina, Douglas Tremblay
Drugs|August 10, 2017
Pharmacotherapy of MyelofibrosisDouglas Tremblay, Bridget Marcellino, John Mascarenhas
Annals of Hematology|March 28, 2022
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directionsHannah Goulart, John Mascarenhas, Douglas Tremblay
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2016
Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future DirectionsSheena Bhalla, Douglas Tremblay, John Mascarenhas
Cancers|January 8, 2023
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet NeedsAngela Liu, Leonard Naymagon, Douglas Tremblay
Pageof 11

Showing results (11-20 of 109) with videos related to

Sort By:
Pageof 11
Cells|April 30, 2021
Next Generation Therapeutics for the Treatment of MyelofibrosisDouglas Tremblay, John Mascarenhas
Best Practice & Research. Clinical Haematology|November 4, 2022
Addressing symptom burden in myeloproliferative neoplasmsDouglas Tremblay, Ruben Mesa
Leukemia & Lymphoma|October 25, 2024
Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategiesSerena Tharakan, Douglas Tremblay, Jacques Azzi
Acta Haematologica|April 7, 2021
The Efficacy of Etoposide-Based Therapy in Adult Secondary Hemophagocytic LymphohistiocytosisLeonard Naymagon, Douglas Tremblay, John Mascarenhas
Current Hematologic Malignancy Reports|July 4, 2025
Contemporary CMML Risk Stratification and ManagementDahniel Sastow, Arjun Syal, Douglas Tremblay
Blood Reviews|July 31, 2023
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatmentChristina Darwish, Kyle Farina, Douglas Tremblay
Drugs|August 10, 2017
Pharmacotherapy of MyelofibrosisDouglas Tremblay, Bridget Marcellino, John Mascarenhas
Annals of Hematology|March 28, 2022
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directionsHannah Goulart, John Mascarenhas, Douglas Tremblay
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2016
Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future DirectionsSheena Bhalla, Douglas Tremblay, John Mascarenhas
Cancers|January 8, 2023
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet NeedsAngela Liu, Leonard Naymagon, Douglas Tremblay
Pageof 11